Independent Research
HIMS Analysis
8 pieces of research on Hims & Hers Health, Inc.. We find the signal management buried in the earnings call.
Hims & Hers Surges on Novo Nordisk Deal, Insiders Sell
Hims & Hers Health stock surged 14% to what news sources called its best single day ever on reports of a Novo Nordisk partnership, incinerating $546 million in …
Read analysis →Hims & Hers Director Bets $1.2M as GLP-1 Battle Heats Up
Director David B Wells purchased $1.17 million in HIMS stock on May 26, days after a 13% earnings-driven drop that Reuters tied to the company's branded weight-…
Read analysis →Hims & Hers Stock Falls 9% After $350 Million Leveraged Acquisition
Hims & Hers upsized a debt raise to $350M to fund the Eucalyptus acquisition alongside an AI initiative, triggering a ~9% share decline as investors questioned …
Read analysis →Hims & Hers Health Faces a 15% Stock Swing on Its Weight-Loss Pivot
Hims & Hers Health heads into Q1 earnings with options traders pricing a ~15% move in either direction, making the print a binary test of whether the GLP-1 weig…
Read analysis →Hims & Hers Health Gets JPMorgan's Blessing at $35 — But the FDA Holds the Real Vote
JPMorgan initiated Hims & Hers Health at Overweight with a $35 price target, while Eli Lilly expanded its LillyDirect GLP-1 partnership, but FDA compounding enf…
Read analysis →